---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-161596"
form_type: "8-K"
ticker: "COGT"
cik: "0001622229"
company_name: "Cogent Biosciences, Inc."
filed_at: "2023-06-06T23:59:59+00:00"
generated_at: "2026-06-14T06:39:02.566332+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cogent Biosciences reports positive Phase 3 PEAK lead-in data for bezuclastinib in GIST

## Summary
- 39 patients treated; 55% disease control rate across efficacy-evaluable patients in Part 1.
- In 2nd-line Part 1a: 100% disease control rate and 17% overall response rate.
- Safety profile well-tolerated; 2 discontinuations due to AEs; low Grade ≥3 events.
- Part 2 enrollment ongoing (target ~388 2nd-line GIST patients); SUMMIT/APEX data expected H2 2023.

## SEC filing metadata
- accession: 0001193125-23-161596
- form_type: 8-K
- ticker: COGT
- cik: 0001622229
- company_name: Cogent Biosciences, Inc.
- filed_at: 2023-06-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1622229/000119312523161596/0001193125-23-161596-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1622229/000119312523161596/d425875d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-161596
- JSON: https://secwatch.observer/filing/0001193125-23-161596.json
- Plain text: https://secwatch.observer/filing/0001193125-23-161596.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.